Propafenone Hydrochloride Injection

1This product belongs to the Ic class (i.e., directly acting on the cell membrane) antiarrhythmic drug. The experimental results of isolated animal myocardium indicate that 0.5-1ug/min can reduce the depolarization effect during contraction, thereby prolonging conduction, slightly prolonging the duration of action potential and the effective refractory period, and can increase the threshold potential of myocardial cells, significantly reducing the spontaneous excitability of the myocardium. It acts on both the atrium and ventricle (mainly affecting the Purkinje fibers, with a smaller effect on the myocardium), and also on the formation and conduction of excitement. Clinical data show that the therapeutic dose (300mg orally and 30mg intravenously) can reduce the irritability of the myocardium, the effect is long-lasting, PQ and QRS are increased, and the effective refractory period of the atrium and atrioventricular node is prolonged. It has an antagonistic effect on various types of experimental arrhythmias. The antiarrhythmic effect is related to its membrane stabilization and competitive blocking effect. It also has a weak calcium antagonist effect (100 times weaker than verapamil), a mild myocardial inhibitory effect, increases end-diastolic pressure, and reduces stroke volume, and its effects are proportional to the dose of the drug. It also has a mild antihypertensive and heart rate-reducing effect. 2 In vitro experiments have shown that propafenone can relax coronary artery and bronchial smooth muscle. 3 It has a local anesthetic effect similar to procaine. 4 Rats took 180-360 mg/kg/day (12-24 times the maximum recommended dose for adults) orally for six months and developed renal function abnormalities, with inflammatory and non-inflammatory reactions in the renal tubules and interstitium. Hepatic fatty degeneration can be found when rats are given 19 times the maximum recommended dose for adults for a long time.

Main ingredients: The main ingredients of this product and its chemical name are: 3-phenyl-1-[2-[3-(propylamino-2-hydroxypropoxy-phenyl]-1-propanone hydrochloride. Molecular formula: Molecular weight: 377

This product is a colorless clear liquid.

It is used to prevent paroxysmal ventricular tachycardia, paroxysmal supraventricular tachycardia, and preexcitation syndrome with supraventricular tachycardia, atrial flutter or atrial fibrillation. It can also be used to treat various premature beats.

Intravenous injection: The usual dose for adults is 1-1.5 mg/kg or 70 mg diluted with 5% glucose solution, slowly injected within 10 minutes, repeated every 10-20 minutes if necessary, with a total amount not exceeding 210 mg. After the intravenous injection takes effect, switch to intravenous drip at a drip rate of 0.5-1.0 mg/minute or oral administration for maintenance.

1. There are fewer adverse reactions, the main ones are dry mouth and numbness of the tongue and lips, which may be due to its local anesthetic effect. In addition, early adverse reactions include headache, dizziness, and glare, followed by gastrointestinal disorders such as nausea, vomiting, and constipation. There are also symptoms of atrioventricular block. There are two reports of cholestatic liver damage after two weeks of continuous use. The activity of each enzyme returned to normal 2 to 4 weeks after discontinuation of the drug. It is believed that this pathological change is due to allergic reactions and individual factors. 2. No damage to the lungs, liver, and hematopoietic system was observed during the trial. A small number of patients experienced mild reactions such as dry mouth, headache, dizziness, and gastrointestinal discomfort mentioned above. Generally, the symptoms disappeared after discontinuation of the drug or reduction of the dosage. There are reports of individual patients experiencing atrioventricular block, prolonged Q-T interval, mild prolongation of P-R interval, prolonged QRS time, etc.

It is contraindicated in patients with sinus node dysfunction without pacemaker protection, severe atrioventricular block, bilateral bundle branch block, severe congestive heart failure, cardiogenic shock, severe hypotension, and those who are allergic to the drug.

Combination with quinidine can slow down the metabolic process. Combination with local anesthetics increases the occurrence of central nervous system side effects. Propafenone can increase serum digoxin concentrations in a dose-dependent manner. Combination with propranolol and metoprolol can significantly increase their plasma concentrations and elimination half-life, but has no effect on propafenone. Combination with warfarin can increase warfarin blood concentrations and prothrombin time. Combination with cimetidine can increase the steady-state level of propafenone in the blood, but has no effect on its electrophysiological parameters.

Keep away from light and store in a sealed container.

20ml:70mg

Shanghai Sine Jinzhu Pharmacy Co., Ltd.

• Founded in:

  1993-12-01

• Address:

  No. 6485, Tingwei Road, Jinshan District, Shanghai

• Tax NO.:

  913101161342488616

• Registered Funds:

  50 million yuan

• Email:

  Log in to view